A prospective study of hemoglobin A1c concentrations and risk of breast cancer in women

Cancer Research

Volumn 66, Issue 5, 2006, Pages 2869-2875

  Lin, Jennifer ^a   Ridker, Paul M ^a   Rifai, Nader ^a,b   Lee, I Min ^a,c   Manson, JoAnn E ^a,b,c   Buring, Julie E ^a,c,d   Zhang, Shumin M ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ESTROGEN RECEPTOR; HEMOGLOBIN A1C; HORMONE; INSULIN; MULTIVITAMIN; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DRUG USE; EVALUATION; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; HYPERINSULINEMIA; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

ADULT; ASPIRIN; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PLACEBOS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; VITAMIN E;

EID: 33645048439     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3922     Document Type: Article

References (49)

1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
2. Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control 2002;13:325-32.
3. Stephenson GD, Rose DP. Breast cancer and obesity: an update. Nutr Cancer 2003;45:1-16.
4. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev 2003;4: 157-73.
5. Newman SC, Lees AW, Jenkins HJ. The effect of body mass index and oestrogen receptor level on survival of breast cancer patients. Int J Epidemiol 1997;26:484-90.
6. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002;20: 1128-43.
7. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91.
8. Elias JJ, Armstrong RC. Brief communication. Hyperplastic and metaplastic responses of human mammary fibroadenomas and dysplasias in organ culture. J Natl Cancer Inst 1973;51:1341-3.
9. Kaleko M, Rutter WJ, Miller AD. Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 1990;10:464-73.
10. Freiss G, Prebois C, Rochefort H, Vignon F. Anti-steroidal and anti-growth factor activities of anti-estrogens. J Steroid Biochem Mol Biol 1990;37:777-81.
11. Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami HO. Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer 1997;71: 360-3.
12. Michels KB, Solomon CG, Hu FB, et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 2003;26:1752-8.
13. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194-202.
14. Adami HO, McLaughlin J, Ekbom A, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991;2:307-14.
15. La Vecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994;70:950-3.
16. Weiss HA, Brinton LA, Potischman NA, et al. Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol 1999;28:816-23.
17. Sellers TA, Anderson KE, Olson JE, Folsom AR. Family histories of diabetes mellitus and breast cancer and incidence of postmenopausal breast cancer. Epidemiology 1998;9:102-5.
18. Bruning PF, Bonfrer JM, van Noord PA, Hart AA, de Jong-Bakker M, Nooijen WJ. Insulin resistance and breast-cancer risk. Int J Cancer 1992;52:511-6.
19. Yang G, Lu G, Jin F, et al. Population-based, case-control study of blood C-peptide level and breast cancer risk Cancer Epidemiol Biomarkers Prev 2001;10:1207-11.
20. Schairer C, Hill D, Sturgeon SR, et al. Serum concentrations of IGF-I, IGFBP-3 and C-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 2004;108:773-9.
21. Malin A, Dai Q, Yu H, et al. Evaluation of the synergistic effect of insulin resistance and insulin-like growth factors on the risk of breast carcinoma. Cancer 2004;100:694-700.
22. Lawlor DA, Smith GD, Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control 2004;15:267-75.
23. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 1998;47:111-20.
24. Muti P, Quattrin T, Grant BJ, et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2002;11:1361-8.
25. Manjer J, Kaaks R, Riboli E, Berglund G. Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the Malmo Preventive Project. Eur J Cancer Prev 2001;10:33-42.
26. Kaaks R, Lundin E, Rinaldi S, et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 2002;13:307-16.
27. Jernstrom H, Barrett-Connor E. Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study. J Womens Health Gend Based Med 1999;8:1265-72.
28. Keinan-Boker L, Bueno De Mesquita HB, Kaaks R, et al. Circulating levels of insulin-like growth factor I, its binding proteins-1, -2, -3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer 2003;106:90-5.
29. Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR. Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol 2002;156:349-52.
30. Rohlfing CL, Little RR, Wiedmeyer HM, et al. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care 2000;23:187-91.
31. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978;200:21-7.
32. Davidson MB, Schriger DL, Peters AL, Lorber B. Revisiting the oral glucose tolerance test criterion for the diagnosis of diabetes. J Gen Intern Med 2000;15:551-5.
33. Goldstein DE, Little RR, Wiedmeyer HM, England JD, McKenzie EM. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986;32:B64-70.
34. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352:1293-304.
35. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294:47-55.
36. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:56-65.
37. Blake GJ, Pradhan AD, Manson JE, et al. Hemoglobin A1c level and future cardiovascular events among women. Arch Intern Med 2004;164:757-61.
38. Osborne CK, Bolan G, Monaco ME, Lippman ME. Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci USA 1976;73:4536-40.
39. Muti P. The role of endogenous hormones in the etiology and prevention of breast cancer: the epidemiological evidence. Ann N Y Acad Sci 2004;1028:273-82.
40. Frystyk J, Vestbo E, Skjaerbaek C, Mogensen CE, Orskov H. Free insulin-like growth factors in human obesity. Metabolism 1995;44:37-44.
41. Nyomba BL, Berard L, Murphy LJ. Free insulin-like growth factor I (IGF-I) in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity. J Clin Endocrinol Metab 1997;82:2177-81.
42. Frisco M, Romano G, Peruzzi F, Valentinis B, Baserga R. Insulin and IGF-I receptors signaling in protection from apoptosis. Horm Metab Res 1999;31:80-9.
43. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215-44.
44. Dupont J, Karas M, LeRoith D. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. J Biol Chem 2000;275:35893-901.
45. Lai A, Sarcevic B, Prall OW, Sutherland RL. Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1). J Biol Chem 2001;276:25823-33.
46. Hamelers IH, van Schaik RF, van Teeffelen HA, Sussenbach JS, Steenbergh PH. Synergistic proliferative action of insulin-like growth factor I and 17β-estradiol in MCF-7S breast tumor cells. Exp Cell Res 2002;273: 107-17.
47. Bartucci M, Morelli C, Mauro L, Ando S, Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res 2001;61:6747-54.
48. Hirose K, Toyama T, Iwata H, Takezaki T, Hamajima N, Tajima K. Insulin, insulin-like growth factor-I and breast cancer risk in Japanese women. Asian Pac J Cancer Prev 2003;4:239-46.
49. Derr R, Garrett E, Stacy GA, Saudek CD. Is HbA(1c) affected by glycemic instability? Diabetes Care 2003;26: 2728-33.